An observational study in Heart Failure, Heart Failure, Diastolic and Heart Failure With Preserved Ejection Fraction (HFPEF), sponsored by Instituto Politécnico de Leiria. Not yet recruiting at 2 sites in Portugal. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-24.
Sponsored by Instituto Politécnico de Leiria · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this observational study is to learn how people with Heart Failure with Preserved Ejection Fraction (HFpEF) can be grouped into different "phenotypes" based on their clinical information. The researchers want to understand whether these groups have different health profiles and different responses during a cardiopulmonary exercise test (CPET).
The main questions this study aims to answer are:
Participants will:
This study includes adults aged 18 years or older who have HFpEF. The study does not involve any new treatments or experimental drugs.
Heart Failure with Preserved Ejection Fraction (HFpEF) is a complex condition, and people with HFpEF can have different symptoms and clinical profiles. Understanding these differences may help improve how the condition is described and studied. This study has two parts: a retrospective analysis and a cross-sectional assessment.
In the retrospective part, the researchers will collect clinical information that was previously recorded in the hospital's clinical records during past hospitalizations for HFpEF at the Local Health Unit of the Leiria Region (ULS RL). The data will be reviewed and prepared for analysis using standard data quality procedures. After the database is complete, the researchers will use data-driven methods to look for patterns among participants, in order to identify groups of people who share similar characteristics ("phenotypes") without setting predefined categories. Methods will include descriptive statistics, correlation analysis and feature selection using algorithmic approaches such as ReliefF. For phenotyping, unsupervised machine-learning techniques including K-means clustering and principal component analysis (PCA) will be applied.
The cross-sectional part will invite a sample of participants selected to represent each phenotype (planned 15 participants for each phenotype) identified in the retrospective analysis. Selected participants will complete a single on-site visit including informed consent verification, a structured clinical review and a standardized cardiopulmonary exercise test (CPET) performed according to local and international guidelines. The CPET procedures will follow the laboratory protocol, namely calibration of equipment, resting measurements, incremental workload protocol, continuous gas exchange, and electrocardiogram (ECG) monitoring. CPET data will be recorded in digital format and transferred securely to the study database.
The study will also evaluate phenotype concordance with widely used HFpEF tools (H2FPEF and HFA-PEFF) and describe differences in physiological responses during CPET across phenotypes, to help clarify how useful they are in describing different forms of HFpEF. Analyses will emphasize exploratory, data-driven evaluation and estimation of effect sizes, consistent with the phenotyping objectives of the study. Where relevant, associations between phenotype membership and CPET variables will be explored descriptively and through correlation-based analyses.
Ethical and data protection procedures are in place. Personal identifiers will be removed and replaced by study ID codes. A linkage file (study ID to personal identifiers) will be stored on an encrypted device with access restricted to the student investigator. Electronic study data will be housed on secure servers with role-based access control. Data will be retained according to institutional policy and relevant legislation. Only de-identified datasets will be used for analysis and sharing. Safety procedures for CPET include pre-test screening for absolute contraindications, continuous ECG and blood pressure monitoring during the test, availability of emergency equipment and immediate clinical oversight by qualified personnel. Adverse events during CPET will be recorded and reported per the Ethics Committee requirements.
By combining clinical record information collected during previous hospitalizations with detailed exercise testing in a selected group, this study aims to provide new insight into the variation that exists among people with HFpEF. The findings may support more personalized approaches in future research.
199 studies on the registry are indexed under Heart Failure, Diastolic; 44 are open to participants now.
This study's planned enrollment of 200 is close to the median of 200 across 55 observational studies indexed under Heart Failure, Diastolic.
Browse Heart Failure, Diastolic studies →Instituto Politécnico de Leiria is the lead sponsor of 20 studies on the registry; 6 are open to participants now.
Compared within Heart Failure, Diastolic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Heart Failure. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Adult patients (≥18 years) with a confirmed diagnosis of heart failure with preserved ejection fraction (LVEF ≥50%) admitted in the Local Health Unit of the Leiria Region since September 2018. The retrospective phase includes electronic health records from approximately 200 patients, used to obtain multimodal datasets for unsupervised clustering. A cross-sectional phase recruits volunteer participants selected for representativeness of the identified phenotypes to undergo cardiopulmonary exercise testing (CPET) for functional characterization. Collected data include sociodemographic variables, clinical history, imaging findings, laboratory biomarkers (e.g., NT-proBNP), therapeutic data and CPET-derived functional parameters.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Retropective observational phase (Phase I):
Cross-sectional observational phase (Phase II - CPET):
Exclusion Criteria:
Retropective observational phase (Phase I):
Cross-sectional observational phase (Phase II - CPET):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single observational cohort including all adults with an established diagnosis of heart failure with preserved ejection fraction (LVEF ≥50%) who received care at the Local Health Unit of the Leiria Region (ULS RL) since September 2018. Clinical, biochemical, imaging, functional, and therapeutic information recorded during previous hospitalizations will be extracted for retrospective analysis. A subset of participants will later be invited to complete a single cardiopulmonary exercise test (CPET) according to the study protocol. Phenotypes (clusters) will be identified post-hoc using unsupervised machine-learning methods and are not predefined at the time of enrollment.
Identification and characterization of HFpEF phenotypes using multimodal clustering analysis
Identification of distinct phenotypic clusters in patients with heart failure with preserved ejection fraction using unsupervised machine learning applied to multimodal clinical, biochemical, imaging and functional data.
Time frame: Up to December 2026 (completion of retrospective data collection and clustering analysis).
Mean peak oxygen uptake (VO₂peak) during cardiopulmonary exercise testing
Peak oxygen uptake (VO₂peak), expressed in mL·kg-¹·min-¹, measured by breath-by-breath gas analysis during maximal cardiopulmonary exercise testing and compared across HFpEF phenotypes.
Time frame: December 2026 to July 2027 (single assessment per participant).
Concordance between H2FPEF and HFA-PEFF scores and identified HFpEF phenotypes
Assessment of concordance and discrimination performance of H2FPEF and HFA-PEFF scores in identifying phenotypes derived from data-driven clustering.
Time frame: Up to October 2027.
Mean plasma NT-proBNP concentration (pg/mL) by HFpEF phenotypes
Comparison of plasma NT-proBNP concentrations (pg/mL) between HFpEF phenotypes identified by clustering analysis.
Time frame: Up to February 2028.
Plan to share: No — Individual participant data (IPD) will not be shared. The dataset contains sensitive clinical and physiological information, including cardiopulmonary exercise test (CPET) variables, with a high risk of reidentification even after de-identification procedures. Institutional policies, local ethics approval, and applicable data protection regulations do not permit external sharing of these data.
Start is estimated for Dec 2026; primary completion for Aug 2027, 8 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Instituto Politécnico de Leiria